|
Fig. 6
PTU and rbp4-MO Treatments Prevent Developmental Abnormalities in stra6 Morphants
(A) rbp4 mRNA expression (blue) was reduced in PTU-treated embryos.
(B) Retinoids (retinaldehyde and RE) of the head and trunk of 4 dpf control and PTU- and rbp4-MO-treated larvae. Values represent the means ± SD of three independent experiments. *p < 0.02 versus control by Student′s t test.
(C) Immunoblot analysis of Rbp4 levels in 24 hpf embryos treated with PTU, PTU and MO2 (left), and rbp4-MO (right) as compared to respective controls. Ponceau S red-stained membranes are shown as a loading control (lower panel).
(D) stra6 morphants and controls were raised in the presence and absence of PTU (n = 170 each). Representative photographs of 3 dpf larvae are shown. PTU treatment prevented developmental abnormalities in 73% of the stra6 morphants. In the absence of PTU, all stra6 morphants displayed cardiac edema (asterisk).
(E) Larvae raised from oocytes either injected with rbp4-MO or coinjected with rbp4-MO and MO2. These morphant larvae were raised in the absence of PTU. rbp4 morphant larvae showed no developmental abnormalities (n = 120). Coinjection of rbp4-MO and MO2 largely prevented developmental abnormalities in 77% of the compound morphants (n = 120).
Scale bar = 100 μM in (A) and 500 μm in (D) and (E). Anterior is to the left in all pictures.
Reprinted from Cell Metabolism, 7(3), Isken, A., Golczak, M., Oberhauser, V., Hunzelmann, S., Driever, W., Imanishi, Y., Palczewski, K., and von Lintig, J., RBP4 Disrupts Vitamin A Uptake Homeostasis in a STRA6-Deficient Animal Model for Matthew-Wood Syndrome, 258-268, Copyright (2008) with permission from Elsevier. Full text @ Cell Metab.